Pneumonia News and Research

Latest Pneumonia News and Research

Remdesivir caused dangerously low heart rate in COVID-19 patients

After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.

25 Jun 2021

Scientists identify new virulence mechanism for a surface protein on pneumonia-causing bacteria

A bout with flu virus can be hard, but when Streptococcus pneumonia enters the mix, it can turn deadly.

24 Jun 2021

Pronation maneuvers for critically ill COVID-19 patients - multidisciplinary management reduce complications

A recent study aimed to determine the efficacy of pronation maneuvers by the ICU physiotherapy team when used on critically ill COVID-19 patients.

24 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

At Texas border, pandemic’s high toll lays bare gaps in health and insurance

Alfredo "Freddy" Valles was an accomplished trumpeter and a beloved music teacher for nearly four decades at one of the city's poorest middle schools.

23 Jun 2021

Health care leaders call for action to prevent non-ventilator-associated, hospital-acquired pneumonia

A group of health care leaders, including a University of Massachusetts Amherst nurse innovator, has published a national call to action to prevent non-ventilator-associated, hospital-acquired pneumonia (NVHAP).

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Do T-cells play a protective immune role, or are they responsible for severe COVID-19 illness?

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

Could a fungus-derived compound reduce hyperinflammation in severe COVID-19?

New research from scientists at the University of Pennsylvania, USA, demonstrates that cyclosporine A (CSA), a calcineurin inhibitor that modulates cytokine production, may have potential antiviral properties against coronaviruses.

18 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

Cinnamon compound could be useful supplement to dexamethasone in COVID-19 treatment

Researchers in Germany and the United States have conducted a study showing that supplementing dexamethasone treatment with Ceylon cinnamon in cases of coronavirus disease 2019 (COVID-19) may allow dexamethasone to be administered at lower doses, thereby avoiding the side effects that occur with high doses of the steroid.

17 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

Study finds low rate of SARS-CoV-2 reinfection for patients with severe illness

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test.

15 Jun 2021

Does SARS-CoV-2 show seasonal variation in transmission in temperate countries?

The need to understand how and why such spread occurs is vital to containing it. A new medRxiv* preprint describes a significant reduction in transmission during the summer (by 42%), which is comparable to the impact of the most effective non-pharmaceutical intervention (NPI).

15 Jun 2021

Carbon-based antimicrobial nanoweapons to fight COVID-19

In a recent review article published in the journal ACS Nano, interdisciplinary researchers from across the world evaluated the role of carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives as promising alternatives to combat COVID-19 (coronavirus disease 2019) and other microbial infections.

15 Jun 2021

Pneumonia News and Research

Latest Pneumonia News and Research

Remdesivir caused dangerously low heart rate in COVID-19 patients

Scientists identify new virulence mechanism for a surface protein on pneumonia-causing bacteria

Pronation maneuvers for critically ill COVID-19 patients - multidisciplinary management reduce complications

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

At Texas border, pandemic’s high toll lays bare gaps in health and insurance

Health care leaders call for action to prevent non-ventilator-associated, hospital-acquired pneumonia

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

Could a fungus-derived compound reduce hyperinflammation in severe COVID-19?

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Cinnamon compound could be useful supplement to dexamethasone in COVID-19 treatment

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

Study finds low rate of SARS-CoV-2 reinfection for patients with severe illness

Does SARS-CoV-2 show seasonal variation in transmission in temperate countries?

Carbon-based antimicrobial nanoweapons to fight COVID-19

COVID-19 in pregnancy could be less severe than previously thought: A Danish case study

Role of traditional medicine against SARS-CoV-2

Children of well-educated parents survive more often than others

Metformin prevents pulmonary or lung inflammation in animals infected with SARS-CoV-2

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pneumonia News and Research

Latest Pneumonia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in